Quantcast
Last updated on April 23, 2014 at 21:24 EDT

Latest Avastin Stories

2010-10-01 14:27:04

Researchers from Boston University School of Medicine (BUSM) and the VA Boston Healthcare System have conducted a study that failed to show a difference in efficacy between Bevacizumab (Avastin) and Ranibizumab (Lucentis) for the treatment of age-related macular degeneration (AMD). The study, which appears currently on-line in Eye, is believed to be the first study to describe one-year outcomes of a prospective, double-masked, randomized clinical trial directly comparing bevacizumab to...

2010-09-01 06:00:00

INCLINE VILLAGE, Nev., Sept. 1 /PRNewswire-FirstCall/ -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced revenue guidance for the third quarter ended September 30, 2010 of approximately $86 million, as compared with actual results of $71.4 million for the third quarter of 2009, a 20 percent year-over-year increase. The growth is primarily driven by increased second quarter 2010 sales of Avastin®, Herceptin®, Lucentis® and...

2010-07-29 07:00:00

NASHVILLE, Tenn. and Glen Rock, N.J., July 29 /PRNewswire/ --HealthLeaders-InterStudy and Fingertip Formulary find that surveyed pharmacy directors whose managed care organizations offer both a Medicare Advantage (MA) and a Part D plan were more than twice as likely to cover Roche/Genentech/Chugai's Avastin and Herceptin for the treatment of multiple cancer indications as a drug benefit on their MA plans as on their stand-alone Part D plans. According to the new Formulary Forum report...

48a1727f8de003247378c30a59ea9b72
2010-07-17 06:40:57

Federal health scientists said Friday that follow-up studies of a Roche breast cancer drug showed it failed to slow tumor growth or extend patient lives. The Food and Drug Administration approved Roche's blockbuster Avastin in 2008 based on early-stage trials after it was seen that it shrank tumors caused by breast cancer.  The decision was controversial because drugs for cancer patients who have never been treated before must show evidence that they extend lives. Avastin's so-called...

2010-05-02 23:01:00

LONDON, May 3, 2010 /PRNewswire/ -- The rheumatoid arthritis treatment Humira will replace Lipitor as the world's biggest-selling drug in 2016, but a familiar name, Pfizer, will still be the biggest seller of medicines after the patent cliff according to the World Preview 2016 report published today by EvaluatePharma, the premier provider of pharma and biotech analysis. The cancer treatment Avastin had been widely expected to emerge as the biggest blockbuster drug following patent...

2010-04-19 08:44:00

NEW YORK, LONDON and BERMUDA, April 19, 2010 /PRNewswire/ -- Celtic Pharmaceutical Holdings L.P. ("Celtic Pharma") today reported at the AACR 101st Annual Meeting 2010 in Washington, DC the results from several preclinical studies of XERECEPT(R) in established models for breast, colon and brain tumors. These animal studies were conducted at Duke University and the Piedmont Research Center using solid human tumors including breast and colon xenografts as well as both pediatric and adult...

2010-01-25 07:30:00

NEW YORK, Jan. 25 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) yesterday reported updated results on the clinical activity of KRX-0401 (perifosine), the Company's PI3K/Akt pathway inhibitor for cancer, in combination with capecitabine (Xeloda®) as a treatment for advanced, metastatic colon cancer. Abstract #447, entitled, "Randomized phase II study of perifosine in combination with capecitabine (P-CAP) versus capecitabine plus placebo (CAP) in...

46cc534a0fae79d6b039eef9687929061
2009-12-20 13:25:50

Up to 25% of cancer patients develop metastases in the brain "“ often long after successful treatment of the primary tumor. In almost all such cases, the prognosis is poor. The mechanisms responsible for the appearance of brain metastases have long been mysterious. Now a research team led by neurologist Dr. Frank Winkler of LMU Munich has followed, in real time, the steps that lead some tumor cells to establish metastases, while others fail to form new tumors. The team also discovered...

2009-12-17 10:30:00

WALTHAM, Mass., Dec. 17 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the cost of Roche/Chugai's Avastin, followed by concerns about its efficacy and side-effect profile, are cited most frequently by surveyed oncologists as the factors preventing their use of Avastin for non-small-cell lung cancer treatment in Germany, France, Italy, Spain and the United Kingdom. The new Special European...

2009-12-15 07:00:00

WALTHAM, Mass., Dec. 15 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that an overall survival benefit would be the most influential factor for three-quarters of surveyed European oncologists in their decision to prescribe a novel agent ahead of Avastin for the treatment of breast cancer. The new Special European Physician & Payer Forum report entitled European Trends in Targeted Therapies in...